Skip to main content
Top
Published in: The Journal of Headache and Pain 4/2009

Open Access 01-08-2009 | Review Article

Favorable outcome of early treatment of new onset child and adolescent migraine-implications for disease modification

Authors: James A. Charles, B. L. Peterlin, Alan M. Rapoport, Steven L. Linder, Marielle A. Kabbouche, Fred D. Sheftell

Published in: The Journal of Headache and Pain | Issue 4/2009

Login to get access

Abstract

There is evidence that the prevalence of migraine in children and adolescents may be increasing. Current theories of migraine pathophysiology in adults suggest activation of central cortical and brainstem pathways in conjunction with the peripheral trigeminovascular system, which ultimately results in release of neuropeptides, facilitation of central pain pathways, neurogenic inflammation surrounding peripheral vessels, and vasodilatation. Although several risk factors for frequent episodic, chronic, and refractory migraine have been identified, the causes of migraine progression are not known. Migraine pathophysiology has not been fully evaluated in children. In this review, we will first discuss the evidence that early therapeutic interventions in the child or adolescent new onset migraineur, may halt or limit progression and disability. We will then review the evidence suggesting that many adults with chronic or refractory migraine developed their migraine as children or adolescents and may not have been treated adequately with migraine-specific therapy. Finally, we will show that early, appropriate and optimal treatment of migraine during childhood and adolescence may result in disease modification and prevent progression of this disease.
Literature
1.
go back to reference Abu-Arefeh I, Russell G (1994) Prevalence of headache and migraine in school children. Br Med J 309:765–769, 1:STN:280:DyaK2M%2Fjsl2msg%3D%3DCrossRef Abu-Arefeh I, Russell G (1994) Prevalence of headache and migraine in school children. Br Med J 309:765–769, 1:STN:280:DyaK2M%2Fjsl2msg%3D%3DCrossRef
2.
go back to reference Split W, Newman W (1999) Epidemiology of migraine among students from randomly selected secondary schools in Lodz. Headache 39:494–501, 11279934, 10.1046/j.1526-4610.1999.3907494.x, 1:STN:280:DC%2BD3M7ovFWktA%3D%3DPubMedCrossRef Split W, Newman W (1999) Epidemiology of migraine among students from randomly selected secondary schools in Lodz. Headache 39:494–501, 11279934, 10.1046/j.1526-4610.1999.3907494.x, 1:STN:280:DC%2BD3M7ovFWktA%3D%3DPubMedCrossRef
3.
go back to reference Monastero R, Camarda C, Pipia C, Camarda R (2006) Prognosis of migraine headaches in adolescents. Neurology 67:1353–1356, 17060559, 10.1212/01.wnl.0000240131.69632.4fPubMedCrossRef Monastero R, Camarda C, Pipia C, Camarda R (2006) Prognosis of migraine headaches in adolescents. Neurology 67:1353–1356, 17060559, 10.1212/01.wnl.0000240131.69632.4fPubMedCrossRef
4.
go back to reference Linder SL (2005) Do children and adolescents have chronic daily headache? Yes!. Curr Pain Headache Rep 9(5):358–362, 16157066, 10.1007/s11916-005-0013-8PubMedCrossRef Linder SL (2005) Do children and adolescents have chronic daily headache? Yes!. Curr Pain Headache Rep 9(5):358–362, 16157066, 10.1007/s11916-005-0013-8PubMedCrossRef
5.
go back to reference Hershey A et al (2001) Characterization of chronic daily headaches in children in a multidisciplinary headache center. Neurology 56:1032–1037, 11320174, 1:STN:280:DC%2BD3M3jtFCrsQ%3D%3DPubMedCrossRef Hershey A et al (2001) Characterization of chronic daily headaches in children in a multidisciplinary headache center. Neurology 56:1032–1037, 11320174, 1:STN:280:DC%2BD3M3jtFCrsQ%3D%3DPubMedCrossRef
6.
go back to reference Stewart WF, Lipton RB, Celentano DD et al (1992) Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. JAMA 267(1):64–69, 1727198, 10.1001/jama.267.1.64, 1:STN:280:DyaK38%2FnvFeksA%3D%3DPubMedCrossRef Stewart WF, Lipton RB, Celentano DD et al (1992) Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. JAMA 267(1):64–69, 1727198, 10.1001/jama.267.1.64, 1:STN:280:DyaK38%2FnvFeksA%3D%3DPubMedCrossRef
7.
go back to reference Stewart WF, Shechter A, Rasmussen BK (1994) Migraine prevalence. A review of population-based studies. Neurology 44(6 Suppl 4):S17–S23, 8008222, 1:STN:280:DyaK2c3nslersw%3D%3DPubMed Stewart WF, Shechter A, Rasmussen BK (1994) Migraine prevalence. A review of population-based studies. Neurology 44(6 Suppl 4):S17–S23, 8008222, 1:STN:280:DyaK2c3nslersw%3D%3DPubMed
8.
go back to reference Welch KMA, Nagesh V, Aurora SK, Gelman N (2001) Periaqueductal gray matter dysfunction in migraine: cause or the burden of illness? Headache 106:81–89 Welch KMA, Nagesh V, Aurora SK, Gelman N (2001) Periaqueductal gray matter dysfunction in migraine: cause or the burden of illness? Headache 106:81–89
9.
go back to reference Kruit MC, van Buchem MA, Hofman PA et al (2004) Migraine as a risk factor for subclinical brain lesions. JAMA 291:427, 14747499, 10.1001/jama.291.4.427, 1:CAS:528:DC%2BD2cXos1Smsg%3D%3DPubMedCrossRef Kruit MC, van Buchem MA, Hofman PA et al (2004) Migraine as a risk factor for subclinical brain lesions. JAMA 291:427, 14747499, 10.1001/jama.291.4.427, 1:CAS:528:DC%2BD2cXos1Smsg%3D%3DPubMedCrossRef
10.
go back to reference Scher AI, Stewart WF, Ricci JA, Lipton RB (2003) Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain 106:81–89, 14581114, 10.1016/S0304-3959(03)00293-8, 1:STN:280:DC%2BD3srgsVGjuw%3D%3DPubMedCrossRef Scher AI, Stewart WF, Ricci JA, Lipton RB (2003) Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain 106:81–89, 14581114, 10.1016/S0304-3959(03)00293-8, 1:STN:280:DC%2BD3srgsVGjuw%3D%3DPubMedCrossRef
11.
go back to reference Kabbouche MA et al (2005) Outcome of a multidisciplinary approach to pediatric migraine at 1, 2, and 5 years. Headache 45:1298–1303, 16324161PubMedCrossRef Kabbouche MA et al (2005) Outcome of a multidisciplinary approach to pediatric migraine at 1, 2, and 5 years. Headache 45:1298–1303, 16324161PubMedCrossRef
12.
go back to reference Charles JA, Jotkowitz S (2005) Observations of the “carry-over effect” following successful termination of chronic migraine in the adolescent with short-term dihydroergotamine, dexamethasone and hydroxyzine: a pilot study. J Headache Pain 6(1):51–54, 16362192, 10.1007/s10194-005-0148-3, 1:CAS:528:DC%2BD2MXhsVaks74%3DPubMedCentralPubMedCrossRef Charles JA, Jotkowitz S (2005) Observations of the “carry-over effect” following successful termination of chronic migraine in the adolescent with short-term dihydroergotamine, dexamethasone and hydroxyzine: a pilot study. J Headache Pain 6(1):51–54, 16362192, 10.1007/s10194-005-0148-3, 1:CAS:528:DC%2BD2MXhsVaks74%3DPubMedCentralPubMedCrossRef
13.
go back to reference Hering-Hanit R, Cohen A, Horev Z (2001) Successful withdrawal from analgesic abuse in a group of youngsters with chronic daily headache. J Child Neurol 16:448–449, 11417614, 1:STN:280:DC%2BD38%2FhsVGrsg%3D%3DPubMedCrossRef Hering-Hanit R, Cohen A, Horev Z (2001) Successful withdrawal from analgesic abuse in a group of youngsters with chronic daily headache. J Child Neurol 16:448–449, 11417614, 1:STN:280:DC%2BD38%2FhsVGrsg%3D%3DPubMedCrossRef
14.
go back to reference Raskin NH, Hosobucki Y, Lamb S (1987) Headache may arise from perturbation of brain. Headache 27:416–420, 3667258, 10.1111/j.1526-4610.1987.hed2708416.x, 1:STN:280:DyaL1c%2Fjt1aqsA%3D%3DPubMedCrossRef Raskin NH, Hosobucki Y, Lamb S (1987) Headache may arise from perturbation of brain. Headache 27:416–420, 3667258, 10.1111/j.1526-4610.1987.hed2708416.x, 1:STN:280:DyaL1c%2Fjt1aqsA%3D%3DPubMedCrossRef
15.
go back to reference Haas DC, Kent PF, Friedman DI (1993) Headache caused by a single lesion of multiple sclerosis in the periaqueductal grey area. Headache 33:452–455, 8262789, 10.1111/j.1526-4610.1993.hed3308452.x, 1:STN:280:DyaK2c%2Fos1eitA%3D%3DPubMedCrossRef Haas DC, Kent PF, Friedman DI (1993) Headache caused by a single lesion of multiple sclerosis in the periaqueductal grey area. Headache 33:452–455, 8262789, 10.1111/j.1526-4610.1993.hed3308452.x, 1:STN:280:DyaK2c%2Fos1eitA%3D%3DPubMedCrossRef
16.
go back to reference Lipton R, Pan J (2004) Is migraine a progressive brain disease? JAMA 291:493–494, 14747508, 10.1001/jama.291.4.493, 1:CAS:528:DC%2BD2cXos12mtA%3D%3DPubMedCrossRef Lipton R, Pan J (2004) Is migraine a progressive brain disease? JAMA 291:493–494, 14747508, 10.1001/jama.291.4.493, 1:CAS:528:DC%2BD2cXos12mtA%3D%3DPubMedCrossRef
17.
go back to reference Marcus D (2003) Central sensitization: an important factor in the pathogenesis of chronic headache. Headache Pain 14(1):19–23 Marcus D (2003) Central sensitization: an important factor in the pathogenesis of chronic headache. Headache Pain 14(1):19–23
18.
go back to reference D’Amico D, Moschiano F, Bussone G (2006) Early treatment of migraine attacks with triptans: a strategy to enhance outcomes and patient satisfaction? Expert Rev Neurother 6(7):1087–1097, 16831121, 10.1586/14737175.6.7.1087PubMedCrossRef D’Amico D, Moschiano F, Bussone G (2006) Early treatment of migraine attacks with triptans: a strategy to enhance outcomes and patient satisfaction? Expert Rev Neurother 6(7):1087–1097, 16831121, 10.1586/14737175.6.7.1087PubMedCrossRef
19.
go back to reference Silberstein SD (2008) Multimechanistic (sumatriptan–naproxen) early intervention for the acute treatment of migraine. Neurology 71:114–121, 18606965, 10.1212/01.wnl.0000316800.22949.20, 1:STN:280:DC%2BD1cvjs1Gjuw%3D%3DPubMedCrossRef Silberstein SD (2008) Multimechanistic (sumatriptan–naproxen) early intervention for the acute treatment of migraine. Neurology 71:114–121, 18606965, 10.1212/01.wnl.0000316800.22949.20, 1:STN:280:DC%2BD1cvjs1Gjuw%3D%3DPubMedCrossRef
20.
go back to reference Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ, Bajwa ZH (2000) An association between migraine and cutaneous allodynia. Ann Neurol 47:614–624, 10805332, 10.1002/1531-8249(200005)47:5<614::AID-ANA9>3.0.CO;2-N, 1:STN:280:DC%2BD3c3mtlSrsA%3D%3DPubMedCrossRef Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ, Bajwa ZH (2000) An association between migraine and cutaneous allodynia. Ann Neurol 47:614–624, 10805332, 10.1002/1531-8249(200005)47:5<614::AID-ANA9>3.0.CO;2-N, 1:STN:280:DC%2BD3c3mtlSrsA%3D%3DPubMedCrossRef
21.
go back to reference Burstein R et al (2004) Defeating migraine pain with triptans: the race against the development of cutaneous allodynia. Ann Neurol 55(1):19–26, 14705108, 10.1002/ana.10786, 1:CAS:528:DC%2BD2cXhtVOnu7g%3DPubMedCrossRef Burstein R et al (2004) Defeating migraine pain with triptans: the race against the development of cutaneous allodynia. Ann Neurol 55(1):19–26, 14705108, 10.1002/ana.10786, 1:CAS:528:DC%2BD2cXhtVOnu7g%3DPubMedCrossRef
22.
go back to reference Waeber C, Moskowitz MA (2003) Therapeutic implications of central and peripheral neurologic mechanisms in migraine. Neurology 61:S9–S20, 14581653PubMedCrossRef Waeber C, Moskowitz MA (2003) Therapeutic implications of central and peripheral neurologic mechanisms in migraine. Neurology 61:S9–S20, 14581653PubMedCrossRef
23.
go back to reference Mathew NT, Kailasam J, Seifert T (2004) Clinical recognition of allodynia in migraine. Neurology 63:848–852, 15365135PubMedCrossRef Mathew NT, Kailasam J, Seifert T (2004) Clinical recognition of allodynia in migraine. Neurology 63:848–852, 15365135PubMedCrossRef
24.
go back to reference Bille B (1997) A 40-year follow-up of school children with migraine. Cephalalgia 17(4):488–491, 9209767, 10.1046/j.1468-2982.1997.1704488.x, 1:STN:280:DyaK2szltlGhtA%3D%3DPubMedCrossRef Bille B (1997) A 40-year follow-up of school children with migraine. Cephalalgia 17(4):488–491, 9209767, 10.1046/j.1468-2982.1997.1704488.x, 1:STN:280:DyaK2szltlGhtA%3D%3DPubMedCrossRef
25.
go back to reference Ferrari A et al (2007) Similarities and differences between chronic migraine and episodic migraine. Headache 47(1):65–72, 17355496, 10.1111/j.1526-4610.2006.00629.xPubMedCrossRef Ferrari A et al (2007) Similarities and differences between chronic migraine and episodic migraine. Headache 47(1):65–72, 17355496, 10.1111/j.1526-4610.2006.00629.xPubMedCrossRef
26.
go back to reference Wober C, Wober-Bingol C, Koch G, Wessely P (1991) Long-term results of migraine prophylaxis with flunarizine and beta-blockers. Cephalalgia 11(6):251–256, 1790569, 10.1046/j.1468-2982.1991.1106251.x, 1:STN:280:DyaK387mtl2ksw%3D%3DPubMedCrossRef Wober C, Wober-Bingol C, Koch G, Wessely P (1991) Long-term results of migraine prophylaxis with flunarizine and beta-blockers. Cephalalgia 11(6):251–256, 1790569, 10.1046/j.1468-2982.1991.1106251.x, 1:STN:280:DyaK387mtl2ksw%3D%3DPubMedCrossRef
27.
go back to reference Solomon S, Lipton R, Newman L (1992) Clinical features of chronic daily headache. Headache 32(7):325–329, 1526762, 10.1111/j.1526-4610.1992.hed3207325.x, 1:STN:280:DyaK38vgs1CgtA%3D%3DPubMedCrossRef Solomon S, Lipton R, Newman L (1992) Clinical features of chronic daily headache. Headache 32(7):325–329, 1526762, 10.1111/j.1526-4610.1992.hed3207325.x, 1:STN:280:DyaK38vgs1CgtA%3D%3DPubMedCrossRef
28.
go back to reference Mathew NT et al (1987) Transformed or evolutive migraine. Headache 27(2):102–106, 3570762, 10.1111/j.1526-4610.1987.hed2702102.x, 1:STN:280:DyaL2s7ptlOlsg%3D%3DPubMedCrossRef Mathew NT et al (1987) Transformed or evolutive migraine. Headache 27(2):102–106, 3570762, 10.1111/j.1526-4610.1987.hed2702102.x, 1:STN:280:DyaL2s7ptlOlsg%3D%3DPubMedCrossRef
29.
go back to reference Fries JF, Williams CA, Morfeld D, Singh G, Sibley J (1996) Reduction in long-term disability in patients with rheumatoid arthritis by disease-modifying antirheumatic drug-based treatment strategies. Arthritis Rheum 39(4):616–622, 8630111, 10.1002/art.1780390412, 1:CAS:528:DyaK28XivVegtLY%3DPubMedCrossRef Fries JF, Williams CA, Morfeld D, Singh G, Sibley J (1996) Reduction in long-term disability in patients with rheumatoid arthritis by disease-modifying antirheumatic drug-based treatment strategies. Arthritis Rheum 39(4):616–622, 8630111, 10.1002/art.1780390412, 1:CAS:528:DyaK28XivVegtLY%3DPubMedCrossRef
30.
go back to reference Fuller G, Bone I (2001) Disease modifying treatment in multiple sclerosis. J Neurol Neurosurg Psychiatry 71(Suppl 1):ii20–ii21, 11701780PubMedCentralPubMed Fuller G, Bone I (2001) Disease modifying treatment in multiple sclerosis. J Neurol Neurosurg Psychiatry 71(Suppl 1):ii20–ii21, 11701780PubMedCentralPubMed
31.
go back to reference Fox A (2008) Disease modification in migraine: study design and sample size implications. Headache 48(8):1169–1175, 18819175, 10.1111/j.1526-4610.2007.01057.xPubMedCrossRef Fox A (2008) Disease modification in migraine: study design and sample size implications. Headache 48(8):1169–1175, 18819175, 10.1111/j.1526-4610.2007.01057.xPubMedCrossRef
32.
go back to reference Fanicullace M, DeCesaris F (2005) Preventing chronicity of migraine. J Headache Pain 6(4):331–333, 10.1007/s10194-005-0224-8CrossRef Fanicullace M, DeCesaris F (2005) Preventing chronicity of migraine. J Headache Pain 6(4):331–333, 10.1007/s10194-005-0224-8CrossRef
33.
go back to reference Petrella R, Speechley M, Kleinstiver P, Ruddy T (2005) Impact of a social marketing media campaign on public awareness of hypertension. Am J Hypertens 18(2):270–275, 15752956, 10.1016/j.amjhyper.2004.09.012PubMedCrossRef Petrella R, Speechley M, Kleinstiver P, Ruddy T (2005) Impact of a social marketing media campaign on public awareness of hypertension. Am J Hypertens 18(2):270–275, 15752956, 10.1016/j.amjhyper.2004.09.012PubMedCrossRef
34.
go back to reference Loder D, Biondi D (2007) Disease modification in migraine: a concept that has come of age? Headache 43(2):135–143, 10.1046/j.1526-4610.2003.03033.xCrossRef Loder D, Biondi D (2007) Disease modification in migraine: a concept that has come of age? Headache 43(2):135–143, 10.1046/j.1526-4610.2003.03033.xCrossRef
35.
go back to reference Bigal ME, Lipton RB (2006) Modifiable risk factors for migraine progression (or for chronic daily headaches)—clinical lessons. Headache 46(Suppl 3):S144–S146, 17034393, 10.1111/j.1526-4610.2006.00566.xPubMedCrossRef Bigal ME, Lipton RB (2006) Modifiable risk factors for migraine progression (or for chronic daily headaches)—clinical lessons. Headache 46(Suppl 3):S144–S146, 17034393, 10.1111/j.1526-4610.2006.00566.xPubMedCrossRef
36.
go back to reference Boardman HF, Thomas E, Millson DS, Croft PR (2006) The natural history of headache: predictors of onset and recovery. Cephalalgia 9:1080–1088, 10.1111/j.1468-2982.2006.01166.xCrossRef Boardman HF, Thomas E, Millson DS, Croft PR (2006) The natural history of headache: predictors of onset and recovery. Cephalalgia 9:1080–1088, 10.1111/j.1468-2982.2006.01166.xCrossRef
37.
go back to reference Hershey A et al (2009) Obesity in the pediatric headache population: a multicenter study. Headache 49:170–177, 18783447, 10.1111/j.1526-4610.2008.01232.xPubMedCrossRef Hershey A et al (2009) Obesity in the pediatric headache population: a multicenter study. Headache 49:170–177, 18783447, 10.1111/j.1526-4610.2008.01232.xPubMedCrossRef
38.
go back to reference Scher AI, Midgette LA, Lipton RB (2008) Risk factors for headache chronification. Headache 48(1):16–25, 18184281PubMedCrossRef Scher AI, Midgette LA, Lipton RB (2008) Risk factors for headache chronification. Headache 48(1):16–25, 18184281PubMedCrossRef
39.
go back to reference Peterlin L, Calhoun A, Siegel S, Mathew N (2008) Rational combination therapy in refractory migraine. Headache 48(6):805–819, 18549358, 10.1111/j.1526-4610.2008.01142.xPubMedCrossRef Peterlin L, Calhoun A, Siegel S, Mathew N (2008) Rational combination therapy in refractory migraine. Headache 48(6):805–819, 18549358, 10.1111/j.1526-4610.2008.01142.xPubMedCrossRef
40.
go back to reference Silberstein SD, Goadsby PJ (2002) Migraine: preventive treatment. Cephalalgia 22:491–512, 12230591, 10.1046/j.1468-2982.2002.00386.x, 1:STN:280:DC%2BD38vovFeluw%3D%3DPubMedCrossRef Silberstein SD, Goadsby PJ (2002) Migraine: preventive treatment. Cephalalgia 22:491–512, 12230591, 10.1046/j.1468-2982.2002.00386.x, 1:STN:280:DC%2BD38vovFeluw%3D%3DPubMedCrossRef
41.
go back to reference Brandes JL, Kudrow D, Stark SR, O’Carroll P, Adelman JU, O’Donnell FJ, Alexander AJ, Spruill SE, Barrett PS, Lener SE (2007) Sumatriptan–naproxen for acute treatment of migraine—a randomized trial. JAMA 297:1443–1454, 17405970, 10.1001/jama.297.13.1443, 1:CAS:528:DC%2BD2sXjvFCjt74%3DPubMedCrossRef Brandes JL, Kudrow D, Stark SR, O’Carroll P, Adelman JU, O’Donnell FJ, Alexander AJ, Spruill SE, Barrett PS, Lener SE (2007) Sumatriptan–naproxen for acute treatment of migraine—a randomized trial. JAMA 297:1443–1454, 17405970, 10.1001/jama.297.13.1443, 1:CAS:528:DC%2BD2sXjvFCjt74%3DPubMedCrossRef
42.
go back to reference Ahoen K et al (2006) A randomized trial of rizatriptan in migraine attacks in children. Neurology 67:1135–1140, 10.1212/01.wnl.0000238179.79888.44CrossRef Ahoen K et al (2006) A randomized trial of rizatriptan in migraine attacks in children. Neurology 67:1135–1140, 10.1212/01.wnl.0000238179.79888.44CrossRef
43.
go back to reference Linder SL (1994) Treatment of childhood headache with dihydroergotamine mesylate. Headache 34(10):578–584, 7843951, 10.1111/j.1526-4610.1994.hed3410578.x, 1:STN:280:DyaK2M7ks1ehsQ%3D%3DPubMedCrossRef Linder SL (1994) Treatment of childhood headache with dihydroergotamine mesylate. Headache 34(10):578–584, 7843951, 10.1111/j.1526-4610.1994.hed3410578.x, 1:STN:280:DyaK2M7ks1ehsQ%3D%3DPubMedCrossRef
44.
go back to reference Winner P et al (2000) A randomized, double blind, placebo controlled study of sumatriptan nasal spray in the treatment of acute migraine in adolescents. Pediatrics 106(5):989–997, 11061765, 10.1542/peds.106.5.989, 1:STN:280:DC%2BD3M%2FlvVKgtQ%3D%3DPubMedCrossRef Winner P et al (2000) A randomized, double blind, placebo controlled study of sumatriptan nasal spray in the treatment of acute migraine in adolescents. Pediatrics 106(5):989–997, 11061765, 10.1542/peds.106.5.989, 1:STN:280:DC%2BD3M%2FlvVKgtQ%3D%3DPubMedCrossRef
45.
go back to reference Linder SL, Dowson A (2000) Zolmatriptan provides effective migraine relief in adolescents. Int J Clin Pract 54:466–469, 11070573, 1:CAS:528:DC%2BD3cXntlGht7k%3DPubMed Linder SL, Dowson A (2000) Zolmatriptan provides effective migraine relief in adolescents. Int J Clin Pract 54:466–469, 11070573, 1:CAS:528:DC%2BD3cXntlGht7k%3DPubMed
46.
go back to reference Charles JA (2006) Almotriptan in the acute treatment of migraine in patients 11–17 years old—a study of efficacy and safety. J Headache Pain 7:95–97, 16688412, 10.1007/s10194-006-0288-0, 1:CAS:528:DC%2BD28XksFCjsbk%3DPubMedCentralPubMedCrossRef Charles JA (2006) Almotriptan in the acute treatment of migraine in patients 11–17 years old—a study of efficacy and safety. J Headache Pain 7:95–97, 16688412, 10.1007/s10194-006-0288-0, 1:CAS:528:DC%2BD28XksFCjsbk%3DPubMedCentralPubMedCrossRef
47.
go back to reference Pageler L, Katsarava Z, Limmroth V et al (2004) Prednisone in the treatment of medication withdrawal headache following medication overuse headache: a placebo-controlled, double-blind, and randomized pilot study. Cephalalgia 24:792 Pageler L, Katsarava Z, Limmroth V et al (2004) Prednisone in the treatment of medication withdrawal headache following medication overuse headache: a placebo-controlled, double-blind, and randomized pilot study. Cephalalgia 24:792
Metadata
Title
Favorable outcome of early treatment of new onset child and adolescent migraine-implications for disease modification
Authors
James A. Charles
B. L. Peterlin
Alan M. Rapoport
Steven L. Linder
Marielle A. Kabbouche
Fred D. Sheftell
Publication date
01-08-2009
Publisher
Springer Milan
Published in
The Journal of Headache and Pain / Issue 4/2009
Print ISSN: 1129-2369
Electronic ISSN: 1129-2377
DOI
https://doi.org/10.1007/s10194-009-0133-3

Other articles of this Issue 4/2009

The Journal of Headache and Pain 4/2009 Go to the issue